Viridian Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa for the treatment of thyroid eye disease (TED), marking the biotechnology company’s first FDA-approved therapy and commercial product. TED is a rare autoimmune disorder that causes inflammation and tissue changes around the eyes, potentially leading to eye protrusion (proptosis), double vision (diplopia), pain and impaired vision.
President and Chief Executive Officer Steve Mahoney said the approval represents a major milestone for both patients with TED and the company. He noted that Lumvoa was developed with patient needs as a priority and described the approval as the result of years of coordinated work across Viridian’s teams. Mahoney added that the company’s commercial and medical affairs organizations have been preparing extensively for the launch, particularly after Lumvoa received FDA Breakthrough Therapy Designation last year, and are ready to support physicians and patients immediately.
Michael Yen, an investigator in the THRIVE clinical program, said the development program comprehensively assessed Lumvoa across both active and persistent forms of thyroid eye disease. According to Yen, the clinical studies demonstrated meaningful improvements in outcomes important to both physicians and patients, including rapid reductions in proptosis and improvements in diplopia, making the therapy a valuable new treatment option for individuals across the full spectrum of TED.
Christine Gustafson, Founder and Chief Executive Officer of the TED Community Organization, welcomed the approval, noting that thyroid eye disease can cause significant physical discomfort as well as emotional distress while substantially disrupting patients’ daily lives. She said the availability of another treatment option could provide meaningful benefits for many individuals seeking effective therapy for the condition.
Viridian said Lumvoa will be available immediately following its FDA approval, with physicians able to begin prescribing the treatment as early as the next day. To support patient access, the company has collaborated with payers, healthcare providers and patient advocacy groups to facilitate broad availability of the therapy. Viridian has also introduced ViridianCare, a patient support program that offers dedicated access specialists and assistance with insurance coverage and benefits verification, as well as financial support for eligible patients to help them and their caregivers navigate treatment and receive the medication without unnecessary barriers.
Lumvoa is a fully antagonistic insulin-like growth factor 1 receptor (IGF-1R) therapy and is the first FDA-approved treatment for thyroid eye disease with labeling supported by data from both active and chronic forms of the disease. In the pivotal THRIVE and THRIVE-2 clinical trials, the therapy achieved both the primary endpoint and all secondary endpoints, demonstrating statistically significant and medically substantial improvements across the major signs and symptoms of thyroid eye disease by the 15th week.
In both pivotal clinical studies, participants were treated with a 12-week course of Lumvoa, a regimen designed to lessen the overall treatment burden for patients. The therapy also demonstrated a rapid onset of action, with clinically meaningful reductions in proptosis, or eye bulging, becoming evident as early as three weeks after treatment began.
Viridian Therapeutics has achieved a significant regulatory milestone after the U.S. Food and Drug Administration (FDA) approved Lumvoa for the treatment of thyroid eye disease (TED). The approval marks an important achievement for Viridian, expanding treatment options for patients living with this rare autoimmune condition that can cause eye inflammation, pain, swelling, double vision, and vision impairment.
The FDA decision strengthens Viridian’s position in the ophthalmology and rare disease markets while supporting the company’s long-term growth strategy.
Viridian Secures FDA Approval for Lumvoa
The FDA approval allows Viridian to commercialize Lumvoa for eligible patients with thyroid eye disease following successful clinical studies that demonstrated its efficacy and safety. The approval reflects the agency’s confidence in the therapy’s clinical benefits and its potential to address an important unmet medical need.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
